Essential Action Publications and Papers

Pharmaceutical Links of NGOs Contributing to the World Health Organization’s Second Public Hearing on Public Health, Innovation and Intellectual Property, November 2007
pdf version: igwg.contributorlinks.pdf

U.S. Compulsory Licensing and Government Use
By Robert Weissman
Presented at the International Conference on Compulsory Licensing, November 22, 2007

Essential Action Director Robert Weissman Testimony to the Senate Judiciary Committee on the Bayh-Dole Act and management of federally funded inventions, October 24, 2007.
Pdf version (warning: 4.5 megabyte file): SenJudiciaryTestimony.10242007.pdf
An rtf version, without appendices: weissman.judiciary.10-24-2007.rtf

Forthcoming from Essential Action and colleague organizations:
TRIPS-Plus Provisions in Trade Agreements: Consequences for Public Health
By Robert Weissman

From the International Journal of Intellectual Property Management:
Public Health-Friendly Options for Protecting Pharmaceutical Registration Data
By Robert Weissman

Forthcoming from the Center for International Environmental Law:
Briefing Note on the Development of U.S. Trade Policy
By Robert Weissman

A cost sharing model to protect investments in pharmaceutical test data
By Judit Rius Sanjuan, James Love, Robert Weissman
May 2006

WTO/TRIPS Agreement and Access to Medicines: Appropriate Policy Responses
Report of the Regional Consultation, organized by Health Action International, Third World Network and the World Health Organization, held in Colombo, Sri Lanka on 17-19 April 2003
Report Prepared by Robert Weissman

Cost Containment Mechanisms for Essential Medicines, Including Antiretrovirals, In China
By German Velasquez, Carlos Correa and Robert Weissman
Health Economics and Drugs, EDM Series No. 13
World Health Organization, 2003

WHO’s Network for Monitoring the Impact of Globalization and TRIPS on Access to Medicines
Meeting Report 19-21 February 2001, Chulalongkorn University, Bangkok, Thailand